| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/21/2005 | US20050159443 For example, N-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-phenyl]-N-methyl-2-[1-methyl-5-(3-methyl-4-nitro-benzoyl)-1H-pyrrol-2-yl]-acetamide; bradykinin receptor agonists; for treating disorders such as pain, inflammation, asthma and allergy |
| 07/21/2005 | US20050159442 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors and methods of using the same |
| 07/21/2005 | US20050159441 Active ingredient and solvent can be stored separately until apparatus is used in a nebuliser; propellant-free; active ingredient is present in highly-concentrated form for storage purposes; inhalers |
| 07/21/2005 | US20050159440 N-substituted groups such as 3-fluoropropyl; 2,2-dimethylethyl; 2-ethoxyethyl; 2-methoxyethyl; 2-propenyl; 2-propynyl; 2-cyanoethyl; 3-cyanopropyl; 3-iodoprop-(2E)-enyl; 3-iodoprop-(2Z)-enyl; therapy for drug abuse, in particular, cocaine abuse; side effect reduction |
| 07/21/2005 | US20050159439 Management of postoperative pain |
| 07/21/2005 | US20050159438 Spirocyclic heterocyclic derivatives and methods of their use |
| 07/21/2005 | US20050159437 Pharmaceutical agents |
| 07/21/2005 | US20050159435 [3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine; selective inhibitors of receptor tyrosine kinases and non-receptor tyrosine kinases (eg: Ick, src, abl) or serine/threonine kinases (e.g.: cyclin dependent kinases); carcinoma |
| 07/21/2005 | US20050159434 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxo-propionitrile mono citrate salt; immunosuppressants, autoimmune diseases, skin disorders, Crohn's disease, antidiabetic agents, anticancer agents, antiarthritic agents |
| 07/21/2005 | US20050159433 Method treatment of transplant rejection |
| 07/21/2005 | US20050159432 Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| 07/21/2005 | US20050159429 Novel crystalline forms of aripiprazole |
| 07/21/2005 | US20050159427 N-acylsulfonamide apoptosis promoters |
| 07/21/2005 | US20050159426 Novartis drug called Imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, methanosulfonate; synergistic mixture with a second antineoplastic agent |
| 07/21/2005 | US20050159425 Inducing tolerance to an antigen by administering to patient a prostaglandin or agonist thereof, a phosphodiesterase inhibitor, and antigen or a derivative thereof; suppressing immune system or an inflammatory response; for example, use of misoprostol and rolipram; antiinflammatory agents, antiallergens |
| 07/21/2005 | US20050159424 pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or C( .dbd. O)NR6, |
| 07/21/2005 | US20050159422 Inhibitors of akt activity |
| 07/21/2005 | US20050159421 Ethylene diamine derivatives and their use as orexin-receptor antagonists |
| 07/21/2005 | US20050159420 Disruption of signal transduction by inhibition of kinases in target cells |
| 07/21/2005 | US20050159419 Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage |
| 07/21/2005 | US20050159418 Nitrogen compounds used as xanthine oxidase inhibitors, for prophylaxis of inflammation, reperfusion injuries, gout or inflammatory bowel disorders |
| 07/21/2005 | US20050159417 Administerng urea derivatives such as1-(3-Cyano-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea for therapy of disease or condition relating to blood coagulation or fibrinolysis |
| 07/21/2005 | US20050159416 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methoxy-pyridin-3-yl)-urea |
| 07/21/2005 | US20050159415 Agents for preventing or ameliorating insulin resistance and /or obesity |
| 07/21/2005 | US20050159414 Inflammatory and obstructive respiratory complaints such as asthma or Chronic obstructive pulmonary disease (COPD); reduced side effects; |
| 07/21/2005 | US20050159411 Bactericides for infrections in man |
| 07/21/2005 | US20050159410 Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 07/21/2005 | US20050159408 Heating a reaction mixture of N-methylpiperazine and thienobenzodiazepine to 110 to 145 degrees C |
| 07/21/2005 | US20050159407 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 07/21/2005 | US20050159406 Treating impaired fundic relaxation; [1(R),[A-(3 alpha ,4 alpha )]]-1-[1-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-3-methoxy-4-piperidinyl]-2(1H)-pyrimidinone |
| 07/21/2005 | US20050159405 Substituted 10-aryl-11h-benzo[b]fluourenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors |
| 07/21/2005 | US20050159404 Organic compound |
| 07/21/2005 | US20050159403 Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage |
| 07/21/2005 | US20050159402 Polyarylcarboxamides useful as lipid lowering agents |
| 07/21/2005 | US20050159401 Treating atheroma, tumors and other neoplastic tissue; treating atherosclerotic inflammation; forming a complexes with a reducing agent, penetrate and accumulate more rapidly in tumor cells, plaque, increase drug in intracellular concentration; increase photosensitivity |
| 07/21/2005 | US20050159400 Manzamines in the treatment of infectious disease |
| 07/21/2005 | US20050159399 Reacting an estradiol with a linking goup slected from a carbonate, a polyoxyethylene glycol and succinic anhydride, an aliphatic diacid, a peptide linkage having 2-15 amia tert-butoxycarbonyl protected cysteic acidno acids |
| 07/21/2005 | US20050159398 17-acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane from diacetylation of the dihydroxy compound followed by selective de-acetylation at position 3 in an acidic aqueous solution; further quaternization with allyl bromide; high yield and purity |
| 07/21/2005 | US20050159397 vitamin D3 derivative as anti-cancer agent, for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion, for immune disorders, metabolic bone diseases and also used as antiinflammatory agent |
| 07/21/2005 | US20050159396 Compositions and methods of treatment for inflammatory diseases |
| 07/21/2005 | US20050159395 Topical applying to skins; skin disorders; anticarcinogenic agents |
| 07/21/2005 | US20050159394 Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets |
| 07/21/2005 | US20050159392 Phosphoramidate linkages; retroviral or hepadnaviral therapy; tissue targeted therapy; HIV/aquired immunodeficiency syndrome; antitumor agents; improved bioavailability |
| 07/21/2005 | US20050159391 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs |
| 07/21/2005 | US20050159390 Treatment and prevention of HIV and other viral infections |
| 07/21/2005 | US20050159389 Combination therapy for treatment of FIV infection |
| 07/21/2005 | US20050159388 Non-nucleotide compositions and method for inhibiting platelet aggregation |
| 07/21/2005 | US20050159387 Combination of ATP-depleting agents (mitochondrial ATP-inhibitor, a methylthioadenosine phosphorylase inhibitor or an inhibitor of De Novo purine synthesis); chemotherapy |
| 07/21/2005 | US20050159385 JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| 07/21/2005 | US20050159383 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) |
| 07/21/2005 | US20050159373 Novel polypeptides, and nucleic acids encoding the same |
| 07/21/2005 | US20050159372 Viramidine (Ribamidine HCL) to treat infections, infestations, tumors and hypersensitivities to autoimmune diseases; viricide; prodrug; less toxic than Ribavirin; selective modulation of Type 1 and Type 2 responses relative to one another for a bimodal effect |
| 07/21/2005 | US20050159371 Process for producing erythromycin a derivative |
| 07/21/2005 | US20050159370 6-11 Bicyclic ketolide derivatives |
| 07/21/2005 | US20050159369 Method of treatment of otitis externa |
| 07/21/2005 | US20050159368 Wound treatment composition and process of manufacture |
| 07/21/2005 | US20050159367 Treatment of DNA viral infections |
| 07/21/2005 | US20050159366 a 6-bromo-3-hydroxyandrostan-17-one compound; viricides; immunosuppressants |
| 07/21/2005 | US20050159365 Hepatits c virus inhibitor comprising alpha-glycosylceramide as the active ingredient |
| 07/21/2005 | US20050159364 Such as trientine; for treatment of neurodegenerative disorders |
| 07/21/2005 | US20050159361 Luteinizing hormone releasing hormone receptor agonist/antagonist (leuprorelin) and steroidal androgen receptor agonist (dehydroepiandrosterone, testosterone); sustained release |
| 07/21/2005 | US20050159360 Improved bioavailability |
| 07/21/2005 | US20050159352 Use of monocarboxylate transporter protein for thyroid hormone transport |
| 07/21/2005 | US20050159351 polynucleotides that bind to proteins that regulate cell growth and division; used as antitumor agents alone or in combination with known cytotoxic agents |
| 07/21/2005 | US20050159347 Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase |
| 07/21/2005 | US20050159341 Scaffolded maleimide clusters for multivalent peptide assembly |
| 07/21/2005 | US20050159337 Use of botulinum toxin therapy for treatment of overactive bladder |
| 07/21/2005 | US20050159334 prophylactic administration; inhibitor has a side chain including a benzamide group to the left and an ester group to the right of a peptide bond; |
| 07/21/2005 | US20050159333 Carbachol, neurokinin A, P2X receptor antagonist, electrical stimulus, to inhibit polypeptide in Rho associated kinase pathway; lower urinary tract disorders, overactive bladder |
| 07/21/2005 | US20050159329 Low reducing sugar content, high level of alpha glucoside bonds, narrow range of high molecular weights, specific branched chain length distribution profile; low intrinsic viscosity; food, and medical applications |
| 07/21/2005 | US20050158835 Preparation of highly polyunsaturated fatty acid-containing phosphatidylserine and phosphatidic acid |
| 07/21/2005 | US20050158785 Non-peptide compounds 2-(5(6)-nitro-2-benzimidazoyl)-5-(4-nitrophenyl)furan; for use in bioassay, fluorescent quantitative analysis; control of gene expression, treatment/prevention of cancer |
| 07/21/2005 | US20050158749 Avermectin aglycon synthase genes |
| 07/21/2005 | US20050158747 Gene therapy; microarrays |
| 07/21/2005 | US20050158726 Compositons and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 07/21/2005 | US20050158724 Methods, of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 07/21/2005 | US20050158713 Fitness assay and associated methods |
| 07/21/2005 | US20050158703 Cytocapacity test for the prediction of the hematopoietic recovery, neutropenic fever, and antimicrobial treatment following high-dose cytotoxic chemotherapy |
| 07/21/2005 | US20050158412 Morinda citrifolia extracts; inhibiting phosphodiesterase 3, Protein-tyrosine phosphatase 1B |
| 07/21/2005 | US20050158409 Beverage with proanthocyanidins; protecting blood vessels |
| 07/21/2005 | US20050158408 Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
| 07/21/2005 | US20050158406 Methods for treating joint inflammation |
| 07/21/2005 | US20050158405 Mixture of one or more alcohol compounds and one or more essential oils containing germicidal properties; applicator |
| 07/21/2005 | US20050158404 Composition and method for treatment of acne |
| 07/21/2005 | US20050158401 Associated with decreased nitric oxide bioavailability; using an arginine- and/or arginase-inhibitor based therapy; asthma, sickle cell disease, and pulmonary hypertension |
| 07/21/2005 | US20050158396 Comprises extracts selected from of Vaccinium myrtillus, Trifolium pratense, Vitis vinifera and Thea vinensis; group consisting of anthocyanosides, isoflavone glucosides and polyphenols; and a co-active component selected from the group consisting tocopherol, ascorbic acid |
| 07/21/2005 | US20050158391 Molten mixture allows the carrier to wet the entire surface of the azithromycin drug crystals allowing the crystals to be fully encapsulated |
| 07/21/2005 | US20050158388 Treatment of gynecomastia with 4-hydroxy tamoxifen |
| 07/21/2005 | US20050158387 Olopatadine formulations for topical administration |
| 07/21/2005 | US20050158386 Process for producing a pharmaceutical solid preparation containing a poorly soluble drug |
| 07/21/2005 | US20050158384 Sustained release delivery of amphetamine salts |
| 07/21/2005 | US20050158383 Quetiapine hemifumarate; sustained release and pulsed release dosage; schizophenia and neuropsychiatric disorders |
| 07/21/2005 | US20050158382 Hydrocodone and acetaminophen; twice-a-day administration; pain relievers |
| 07/21/2005 | US20050158380 Sustained release oral dosage forms of gabapentin |
| 07/21/2005 | US20050158379 Minimization of drug oxidation in drug irradiated excipients formulations |
| 07/21/2005 | US20050158376 Dietary supplement and method of processing same |
| 07/21/2005 | US20050158374 Compositions and dosage forms for enhanced absorption of metformin |
| 07/21/2005 | US20050158371 Ointment, cream containing SMP-114 or leflunomide; N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; antiinflammatory or antirheumatic |
| 07/21/2005 | US20050158361 prosthesis, shunt, catheter or local drug delivery device with coating of a biocompatible oil or fat containing a therapeutic agent; e.g. cod liver oil or olive oil and alpha-tocopherol |
| 07/21/2005 | US20050158360 From a two-layered polymeric matrix including incompatible polymers, the top layer controls elution rate of said drugs; e.g. fluoropolymer layer covered with a polyacrylate top layer; stents, anastomotic devices |